Our community is in need of improved care for patients with malignant diseases, especially our minority population. Our long-term goals are to bring the advantages of cancer control and state-of-the-art cancer treatment to a much larger number of patients in our target population. In order to enhance the accrual of patients, especially minority patients, we need to dramatically expand our support structure. We have a strong history of a multi-disciplinary effort in cancer care by a large number of health care professionals, which can potentially reduce the morbidity and mortality as well as the cancer incidents in this targeted population. Unfortunately, we have had a dearth of support personnel required to expand our work. This proposal aims to dramatically increase the Data Management personnel and support structure needed to provide ample opportunity to expand our clinical cancer research. Our multi-center approach allows us access to two of the three largest urban areas with the highest concentration of minorities. This is important since minority accrual to NCI cancer research protocols has been so poor. By enrolling more of this underserved population to national trials, it is hoped that the overall care of this population can be improved. This is an ambitious multi-center approach, using a centralized data management system, to recruit and follow-up patients. Epidemiologists at our institution have identified excess mortality compared to the incidence of many cancers. Excess mortality is especially found among the minority population of the state. Efforts are underway within the state to determine the high mortality compared to incidence for these cancers but the main factor appears to be delay in diagnosis. Access to care, per se, is not a factor since Louisiana is unique among states in having a state-wide, state-run system for indigent care. Despite this system, patients do not appear to present for diagnosis in a timely fashion. Factors which could effect patient delay in diagnosis are lack of information about cancer screening. LSU has participated in several cooperative trial groups and has a proven commitment to enrollment of all investigators into one organizational structure with centralized data management, thus eliminating duplication. Streamlining this operation will allow greater access to new populations in the southern part of the state. Increasing enrollments in cancer treatment and control trials should have an enhanced effect in promoting screening and earlier access to care for all the citizens of the state, especially the minority populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA063845-06S5
Application #
6331457
Study Section
Special Emphasis Panel (ZCA1 (J3))
Project Start
1994-08-12
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2001-05-31
Support Year
6
Fiscal Year
2000
Total Cost
$77,070
Indirect Cost
Name
Louisiana State University Hsc New Orleans
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13
Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900
Stiff, Patrick J; Unger, Joseph M; Cook, James R et al. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369:1681-90
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61

Showing the most recent 10 out of 66 publications